A Survey of Venous Thromboembolism (VTE) Prophylaxis in Obstetrics Patients in Iran

  • Majid Mokhtari Department of Internal Medicine, Shahid Beheshti University of Medical Sciences, Imam Hosein Hospital, Tehran, Iran
  • Khadijeh Nasri Department of Obstetrics and Gynecology, Arak University of Medical Sciences, Arak, Iran
  • Fatemeh Tara Department of Obstetrics and Gynecology, Mashhad University of Medical Sciences, Ommol Banin Teaching Hospital, Mashhad, Iran
  • Elahe Zarean Department of Obstetrics and Gynecology, Isfahan University of Medical Sciences, Alzahra Teaching Hospital, Isfahan, Iran
  • Sedigheh Hantoushzadeh Maternal-Fetal Medicine Research Center, Tehran University of Medical Sciences, Imam Khomeini Teaching Hospital, Tehran, Iran
  • Mehrnaz Radmehr Department of Obstetrics and Gynecology, Milad Hospital, Tehran, Iran
  • Maryam Kashanian Department of Obstetrics and Gynecology, Iran University of Medical Sciences, Akbarabadi Teaching Hospital, Tehran, Iran
Keywords: Venous Thrombo-embolism, Obstetric Population, Deep Venous Thrombosis, VTE Prophylaxis, Pulmonary Embolism

Abstract

Objective: The purpose of the present study was a survey of venous thromboembolism (VTE) prophylaxis in obstetrics patients in Iran.Materials and methods: A national, multicenter, non-interventional, prospective study was performed on 1000 women at 11 different parts of Iran. Primary outcome was to assess the situation of VTE prophylaxis in pregnant and postpartum women and the secondary outcome was risk stratification in obstetrics patients and to evaluate the guideline adherence in physician’s practice of VTE prophylaxis.Results: 1,036 women entered the final analysis. The three main VTE risk factors before hospitalization were BMI > 30 kg/m2, history of oral contraceptive (OCP) use, and the age over 35.VTE risk factors upon enrollment were detected in 780 (75.28%) patients. 219 women (28.07%) were deemed eligible for drug prophylaxis, however, only 37 women (17%) received it. A total of 113 (10.9%) patients received VTE prophylaxis, of which 76 (67.25%) women had no clear indications. Concordance between theory and practice was detected with a Cohen’s Kappa coefficient to be 0.74 (p < 0.001), which fell within “good agreement”. Multivariate analysis for association between VTE prophylaxis and VTE risk factors showed that history of VTE [OR = 9.06 (CI 95% 1.16 – 70.8) p = 0.036] was the most frequent risk factor for receiving VTE prophylaxis followed by obesity (BMI > 30 Kg/m2); [OR = 3.74 (CI 95% 1.79 – 5.69), p = <0.001], multiple pregnancy [OR= 2.81 (CI 95% 1.70 – 4.64), p = < 0.001] and age > 35 years; [OR =1.09 (CI 95% 0.82 – 1.21), p = 0.026]. Varicose Veins [OR= 0.22 (CI 95% 0.56 – 0.87), p = 0.031], PROM / PPROM [OR= 0.33 (CI 95% 0.12 – 0.91), p = 0.032] and history of using OCP [OR= 0.36 (CI 95% 0.24 – 0.53), p = < 0.001] were the most missed risk factors for receiving VTE prophylaxis respectively. Conclusion: History of VTE, obesity, multiple pregnancy and age > 35 years were the most frequent risk factors for receiving VTE prophylaxis and varicose veins, PROM / PPROM and history of using OCP were the most missed risk factors for receiving VTE prophylaxis.

References

1. Berman KA. Haemostatic changes in pregnancy. Best Prac Res Clin Haematol 2003; 16: 153-68.
2. Royal College of Obstetricians and Gynecologists.
Reducing the risk of thrombosis and embolism during pregnancy and the puerperium. Green-top Guideline No. 37a. London: RCOG; 2009.
3. Chang J, Elam-Evans LD, Berg CJ, Herndon J, Flowers L, Seed KA, et al. Pregnancy-related mortality surveillance--United States, 1991--1999. MMWR Surveill Summ 2003; 52:1-8.
4. Knight M; UKOSS. Antenatal pulmonary embolism: risk factors, management and outcomes. BJOG 2008; 115:453–61.
5. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ 3rd. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005; 143:697-706.
6. Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJ. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost 2008; 6:632–7.
7. Liu S, Liston RM, Joseph KS, Heaman M, Sauve R, Kramer MS; Maternal Health Study Group of the Canadian Perinatal Surveillance System. Maternal mortality and severe morbidity associated with low-risk planned cesarean delivery versus planned vaginal delivery at term. CMAJ 2007; 176: 455–60.
8. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e691S-e736S.
9. Virkus RA, Løkkegaard E, Lidegaard Ø, Langhoff-Roos J, Nielsen AK, Rothman KJ, et al. Risk Factors for Venous Thromboembolism in 1.3 Million Pregnancies: A Nationwide Prospective Cohort. PLoS One 2014; 9: e96495.
10. Tsikouras P, von Tempelhoff GF, Rath W. Epidemiology, Risk Factors and Risk Stratification of Venous Thromboembolism in Pregnancy and the Puerperium. Z Geburtshilfe Neonatol 2017; 221: 161-74.
11. Heit JA, Ashrani A, Crusan DJ, McBane RD, Petterson TM, Bailey KR. Reasons for the persistent incidence of venous thromboembolism. Thromb Haemost 2017; 117: 390-400.
12. Heit JA. Epidemiology of venous thrombo embolism. Nat Rev Cardiol 2015; 12: 464-74.
Published
2019-07-28
How to Cite
1.
Mokhtari M, Nasri K, Tara F, Zarean E, Hantoushzadeh S, Radmehr M, Kashanian M. A Survey of Venous Thromboembolism (VTE) Prophylaxis in Obstetrics Patients in Iran. J Fam Reprod Health. 13(1):21-25.
Section
Original Articles